Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Larger targeted population
4.1.1.2. Development of therapies
4.1.2. Restraints:
4.1.2.1. Side-effects associated with the use of therapies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
6. By Drug Class
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
6.1.2. Market Attractiveness Index, By Drug Class Segment
6.2. Analgesics
6.2.1.1. Introduction
6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
6.3. Antidepressants
6.4. Oral Contraceptives
6.5. Ovarian Suppression Agents
6.6. Gonadotropin-releasing hormone (GnRH) Analogues
6.7. Estrogen-only patches & implants
6.8. Selective serotonin reuptake inhibitors (SSRIs)
6.9. Others
7. By Distribution Channel
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
7.1.2. Market Attractiveness Index, By Distribution Channel Segment
7.2. Hospital Pharmacies
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Drug Stores and Retail Pharmacies
7.4. Online providers
7.5. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. Australia
8.5.5.5. Rest of Asia Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9. Competitive Landscape
9.1. Key Developments and Strategies
9.2. Company Share Analysis
9.3. Drug Classs Benchmarking
9.4. List of Key Companies to Watch
10. Company Profiles
10.1. Bayer AG
10.1.1. Company Overview
10.1.2. Drug Class Portfolio and Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Eli Lilly And Company
10.3. GlaxoSmithKline Plc.
10.4. H. Lundbeck A/S
10.5. Pfizer Inc.
10.6. Asarina Pharma AB
10.7. Chattem, Inc. (Sanofi)
10.8. Dekk-Tec
10.9. Pherin Pharmaceuticals
10.10. Novartis International AG
LIST NOT EXHAUSTIVE
11. Global Premenstrual Syndrome Treatment Market – DataM
11.1. Appendix
11.2. About Us and End User
11.3. Contact Us